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Abstract
Introduction: Assessment of treatments for acute respiratory distress syndrome (ARDS) has focused on short-term
outcomes (for example, mortality); little information exists regarding long-term effects of ARDS treatment. Survivors
of ARDS episodes may have long-term obstructive/restrictive pulmonary abnormalities and pulmonary gas
exchange impairment. A 2004 prospective randomized placebo-controlled trial assessed the efficacy and safety of
inhaled nitric oxide (iNO) in patients with non-septic ARDS; the primary endpoint was days alive and off assisted
breathing. This analysis examined potential effects of iNO or placebo on pulmonary function six months post-
treatment in ARDS survivors from that original study.
Methods: ARDS survivors (N = 92) from a large-scale randomized, placebo-controlled study evaluating mortality
after either 5 ppm iNO or placebo for up to 28 days were assessed six months post-treatment. Pulmonary function
testing across seven parameters was conducted.
Results: At 6 months post-treatment, results indicated significantly better absolute values for iNO versus placebo
for mean ± SD total lung capacity (TLC, 5.54 ± 1.42 vs. 4.81 ± 1.00; P = 0.026). There were also significantly better
values for mean ± SD percent predicted values for a) forced expiratory volume in 1 second (FEV1, 80.23 ± 21.21 vs.
69.51 ± 28.97; P = 0.042), b) forced vital capacity (FVC, 83.78 ± 19.37 vs. 69.84 ± 27.40; P = 0.019), c) FEV1/FVC
(96.14 ± 13.79 vs. 87.92 ± 19.77; P = 0.033), and d) TLC (93.33 ± 18.21 vs. 76.10 ± 21.84; P < 0.001). Nonsignificant
differences were found in absolute FEV1, FEV1/FVC, FVC, forced expiratory flow from 25% to 75% of FVC, functional
residual capacity, and CO diffusion.
Conclusions: ARDS patients surviving after treatment with low-dose iNO had significantly better values for select
pulmonary function tests at six months post-treatment than placebo-treated patients. Further trials are warranted
to determine the effects of iNO on chronic lung function in ARDS survivors, a factor in long-term morbidity and
quality of life in this population.
Trial Registration: A Double-blind, Randomized, Placebo-controlled, Dose-response Study of Inhaled Nitric Oxide
in the Treatment of Acute Respiratory Distress Syndrome. NCT number: ISRCTN53268296
Introduction
Inhaled nitric oxide (iNO) is a vasodilator indicated for
treatment of term and near-term neonates with hypoxic
respiratory failure associated with clinical or echocardio-
graphic evidence of pulmonary hypertension. In these
patients, iNO has been shown to improve oxygenation
and reduce the need for extracorporeal membrane oxy-
genation therapy [1]. NO binds to and activates cytoso-
lic guanylate cyclase, thereby increasing intracellular
levels of cyclic guanosine 3’,5’-monophosphate (cGMP).
This, in turn, relaxes vascular smooth muscle, leading to
vasodilatation. iNO selectively dilates the pulmonary
vasculature, with minimal systemic vasculature effect as
a result of efficient hemoglobin scavenging. In acute
* Correspondence: dellinger-phil@cooperhealth.edu
1Division of Critical Care Medicine, Department of Medicine, Cooper
University Hospital, 1 Cooper Plaza, Camden, NJ 08103, USA
Full list of author information is available at the end of the article
Dellinger et al. Critical Care 2012, 16:R36
http://ccforum.com/content/16/2/R36
© 2012 Dellinger et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
lung injury (ALI) and acute respiratory distress syn-
drome (ARDS), increases in partial pressure of arterial
oxygen (PaO2) are believed to occur secondary to pul-
monary vessel dilation in better-ventilated lung regions.
As a result, pulmonary blood flow is redistributed away
from lung regions with low ventilation/perfusion ratios
toward regions with normal ratios [1-3].
The incidence of ARDS has been estimated to be
approximately 75 cases per 100,000 population, although
this figure is impacted by ambiguity in the causes and
manifestations of ARDS [4,5]. Mortality rates in ARDS
are substantial, with estimates ranging from 34% to 68%
[4], highlighting the need for effective treatment.
Many pharmacologic treatments have been investi-
gated in ARDS patients, including alprostadil [6], acetyl-
cysteine [7], corticosteroids [8], surfactant [9], dazoxiben
[10] and acyclovir [11]. All studies to date have focused
on mortality as the primary endpoint. A meta-analysis
of trials completed through 2004 indicated limited mor-
tality benefit with any of the above-mentioned treat-
ments [12].
Patients surviving an episode of ARDS may have long-
term obstructive and restrictive pulmonary abnormal-
ities as well as pulmonary gas exchange impairment
[13-15]. These long-term effects may contribute to
decreased quality of life (QoL), repeatedly demonstrated
by ARDS survivors [13,16,17]. The importance of long-
term effects following an ARDS episode has recently
emerged, with clinicians noting that assessing short-
term survival of ARDS is only part of its clinical impact.
Therefore, treatments provided in the ICU that improve
long-term ARDS outcomes (without improving immedi-
ate survival) and clinical studies examining treatment
effects on later outcomes may be relevant [18].
A large-scale, randomized, blinded, placebo-controlled
study carried out in the ICUs of 46 US hospitals evalu-
ated the efficacy of low-dose (5 ppm) iNO in 385
patients with moderately severe ALI. The primary end-
point was number of days alive and off assisted breath-
ing. Results of an intent-to-treat analysis revealed that
iNO had no significant benefit versus control (nitrogen
gas) as it related to mortality (23% versus 20%, respec-
tively), days alive and off assisted breathing (mean, 10.7
versus 10.6 days), or days alive and meeting oxygenation
criteria for extubation (mean, 16.7 versus 17.0 days).
Treatment, however, resulted in a significant increase (P
< 0.05) in PaO2 during the initial 24 hours of treatment,
with improvement resolved by 48 hours [19].
Safety results for the initial 28-day study period have
been reported [19] and are summarized briefly here. A
total of 630 adverse events (AEs) were reported for
patients treated with iNO versus 666 events for those
receiving placebo. Respiratory system AEs occurred in
51% versus 61% of patients receiving iNO and placebo,
respectively, primarily due to higher frequencies of
pneumonia, pneumothorax, and apnea in the placebo
group. Frequency of other AEs was similar in both
groups [19].
The present analysis was developed a priori as part of
the original study protocol and assessed long-term pul-
monary function differences between iNO and placebo
at six months post-treatment. The original rationale for
long-term follow-up of pulmonary function in survivors
was to assess both the safety of iNO use in ARDS and
to examine any potential efficacy on the incidence of
chronic lung disease in survivors. This study is the first
prospective long-term analysis of pulmonary function in
ARDS survivors participating in a randomized interven-
tional clinical trial comparing iNO and placebo.
Materials and methods
The protocol, amendments to the protocol, and local
Informed Consent Forms were reviewed and approved
by each of the participating hospitals’ Institutional
Review Board prior to initiation of patient accrual.
Inclusion and exclusion criteria and treatment details
for this analysis are described elsewhere [19]; they are
summarized briefly here.
Patients
Patients had moderately severe ALI, defined by a modi-
fication of American-European Consensus Conference
criteria (PaO2/fraction of inspired oxygen [FiO2] ratio of
≤ 250 mm Hg), due to causes other than severe sepsis.
Patients with evidence of non-pulmonary system failure
at the time of randomization and sepsis-induced ARDS
were excluded. Patients were also excluded if they had
sustained hypotension requiring vasopressor support,
hemodynamic profiles supporting severe sepsis, severe
head injury, severe burns or evidence of other significant
organ system dysfunction at baseline [19].
Treatment
Patients were randomly assigned to receive either
inhaled placebo (nitrogen) or 5 ppm of iNO (INO Ther-
apeutics Inc., Port Allen, LA, USA). Patients, healthcare
professionals, and investigators were blinded to the
assigned treatment. iNO was administered via INOvent®
delivery system (Datex-Ohmeda, Madison, WI, USA)
that blended the treatment drug (nitrogen or NO at
100-ppm balance nitrogen) 1:20 with ventilator gases to
achieve a target ppm value in the inspiratory limb of the
ventilator [19].
All patients using the iNO delivery system received
mechanical ventilatory support. Treatment continued
with active or placebo gas until one of the following cri-
teria was met: 1) end of trial (28 days); 2) death; or 3)
adequate oxygenation (arterial oxygen saturation by
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pulse oximetry [SpO2] ≥ 92% or PaO2 of ≥ 63 mm Hg)
without treatment at ventilator settings of FiO2 ≤ 0.4
and positive end-expiratory pressure (PEEP) of ≤ 5 cm
H2O. Decreases in treatment gas continued in 20%
decrements (titrated down by 1 ppm for iNO) every 30
minutes until either the drug concentration reached 0%
or oxygenation criteria were not satisfied. If oxygenation
criteria were not met, drug concentration was titrated
up until they were again achieved. Increments of upward
titration were determined by the clinician, based on
degree of arterial desaturation [19].
Respiratory parameters measured during hospitalization
Baseline oxygenation measures included PaO2, arterial
partial pressure of CO2 (PaCO2), SpO2, FiO2, PEEP,
PaO2/FiO2 ratio, ventricular rate, tidal volume, and
mean airway pressure. Respiratory parameters (FiO2,
PEEP, and PaO2/FiO2 ratio) were recorded on case
report forms every 12 hours during mechanical
ventilation.
Long-term pulmonary function measures
Pulmonary function testing (PFT) at six months post-
treatment was required in both iNO- and placebo-trea-
ted patients as part of the original study design. PFTs
included FEV1, FEV1 % predicted, FVC, FVC % pre-
dicted, the FEV1/FVC ratio, FEV1/FVC ratio % pre-
dicted, forced expiratory flow (FEF) from 25% to 75% of
FVC (FEF25-75%), FEF25-75% % predicted, functional resi-
dual capacity (FRC), FRC % predicted, total lung capa-
city (TLC), TLC % predicted, CO diffusion, and CO
diffusion % predicted.
Statistical methods
All between-group differences in PFT results were eval-
uated using the Wilcoxon rank sum test. Between-group
differences in baseline clinical and demographic charac-
teristics were assessed with either Fisher’s exact test or
chi-square test for categorical variables and with Wil-
coxon rank sum test for continuous variables. Baseline
oxygenation and respiratory/oxygenation parameters in
the two groups were compared using Wilcoxon rank
sum tests. The areas under the curve (AUCs) of FiO2
and PEEP were calculated using the trapezoidal rule to
demonstrate the total exposure of both groups during
days of mechanical ventilation to supplemental oxygen
and PEEP from Baseline through day 28 or day of dis-
charge, inclusive. The null hypothesis that the respective
AUCs were normally distributed was rejected employing
the Shapiro-Wilk test. A Wilcoxon rank sum test was
utilized to assess the differences in each median AUC
between treatment groups. A P value < 0.05 was consid-
ered significant.
Results
Demographics and baseline characteristics
Final disposition of all subjects in the original study and
six-month follow-up is shown in Figure 1. A total of 302
patients were survivors (alive, on or off assisted breathing)
after the initial 28-day treatment period (148 in the iNO
group, 154 placebo). Of these, 92 (30%) were capable of
and participated in the six-month follow-up pulmonary
function evaluations, 51 (55%) in the iNO group and 41
(45%) in the placebo group. The remaining surviving sub-
jects (n = 210) either died prior to follow-up (n = 20),
were lost to follow-up (n = 47), or did not have available
PFT data (n = 143). Baseline patient characteristics are
summarized in Table 1. The two treatment groups were
well matched for all demographic variables. There were no
significant differences between groups with respect to
ARDS etiology, severity of illness, frequency of co-morbid
chronic respiratory conditions or use of inhaled corticos-
teroids. More subjects had a history of tobacco use in the
iNO group (26 versus 17, P = 0.41). There were more pla-
cebo patients who had evidence of morbid obesity (actual
body weight is ≥ 35% over ideal body weight) (19 versus
13, P = 0.028). Regardless of the presence or absence of
morbid obesity, analyses showed that the treatment effect
remained the same.
Baseline oxygenation parameters
Baseline oxygenation parameters, including PaO2,
PaCO2, SpO2, FiO2, PEEP, and PaO2/FiO2 ratio are
summarized in Table 2. The patients included in this
analysis were severely ill with mean baseline PaO2/FiO2
ratios of 140.5 ± 43.4 (iNO) and 136.1 ± 40.4 (placebo).
Except for a clinically insignificant difference in SpO2,
there were no significant between-group differences
with respect to baseline oxygenation parameters.
Baseline respiratory parameters
Baseline respiratory parameters, including ventilator
rate, tidal volume, and mean airway pressure are also
summarized in Table 2. There were no significant differ-
ences between groups for any of these measures.
Respiratory parameters during mechanical ventilation
There were no significant differences between groups
for aggregate daily per-patient changes from baseline
parameters in supplemental oxygen, PEEP, or PaO2/
FiO2 ratio for patients receiving mechanical ventilation
(Figures 2, 3 and 4).
However, when calculating the duration of exposure
(AUC) over the length of mechanical ventilation for
total FiO2 (6.3 ± 4.5 versus 7.6 ± 4.7 (%days) for iNO
and placebo groups, respectively; P = 0.151) and total
PEEP (96.3 ± 75.9 versus 113.4 ± 81.1 (mmHgdays), P =
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Figure 1 Disposition of subjects. AOAB, alive and off assisted breathing by day 28; NO, nitric oxide; PFT, pulmonary function test.
Table 1 Baseline demographic and clinical characteristics
Parameter Placebo Inhaled NO P Value
Age, years N 41 51
Mean ± SD 47.8 ± 16.7 45.3 ± 15.3 0.494
Range 18.4 - 84.0 16.8 - 77.9
Sex, n (%) Male 19 (46%) 25 (49%) 0.836
Female 22 (54%) 26 (51%)
Race, n (%) Caucasian 35 (85%) 42 (82%) 0.847
Black 4 (10%) 5 (10%)
Other 2 (5%) 4 (8%)
Height, cm N 39 51
Mean ± SD 168.7 ± 11.4 169.4 ± 9.2 0.912
Weight, kg N 41 51
Mean ± SD 85.7 ± 24.1 76.4 ± 19.2 0.049
BW ≥ 35% IBW N 19 (46.3%) 13 (25.5%) 0.028
Causes of ARDS,a n (%)
Pneumonia 20 (49%) 15 (29%) 0.084
Toxic gas inhalation 0 (0%) 0 (0%) 1.000
Acute pancreatitis 1 (2%) 3 (6%) 0.626
Massive blood transfusion 5 (12%) 10 (20%) 0.404
Fat emboli 1 (2%) 2 (4%) 1.000
Aspiration pneumonitis 9 (22%) 9 (18%) 0.610
Pulmonary contusion 6 (15%) 12 (24%) 0.307
Postpartum ARDS 2 (5%) 0 (0%) 0.196
Multiple trauma 14 (34%) 15 (29%) 0.657
Elective or emergency surgical procedures 9 (22%) 20 (39%) 0.114
Patient History, n (%)
Preexisting steroid use 3 (7%) 8 (15%) 0.334
Asthma 4 (10%) 5 (10%) 1.000
COPD 6 (15%) 6 (12%) 0.761
Tobacco use 17 (41%) 26 (51%) 0.405
aPatients may have more than one cause of ARDS. ARDS, acute respiratory distress syndrome; BW, body weight; COPD, chronic obstructive pulmonary disorder;
IBW, ideal body weight; N, number; NO, nitric oxide.
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0.261), although not statistically significant, the iNO
group did have less cumulative exposure to both vari-
ables (Table 3).
Pulmonary function tests at six months
Results for PFTs at six months post-treatment with pla-
cebo or iNO are summarized in Table 4 and presented
as comparison percent between treatment groups in Fig-
ure 5. Study results indicated significantly better values
for patients treated with iNO versus placebo for FEV1 %
predicted (P = 0.042), FVC % predicted (P = 0.019),
FEV1/FVC % predicted (P = 0.033), TLC (P = 0.026),
and TLC % predicted (P < 0.001). No significant differ-
ences were observed in FEV1, FEV1/FVC, FVC, FEF25-
75%, FRC, or CO diffusion values, nor for percent pre-
dicted values for FEF25-75%, FRC, and CO diffusion.
Baseline characteristics of survivors and patients with no
follow-up at six months
Table 5 shows that the two treatment groups were well
matched for all demographic variables except for a slight
but statistically significant difference in age and the inci-
dence of other types of preexisting lung disease with the
patients without six month follow-up data being slightly
older and having a greater incidence of preexisting lung
disease of ‘other’ etiologies.
Discussion
Clinical trials evaluating numerous interventions have
repeatedly failed to demonstrate significant benefit in
decreasing mortality in ARDS patients [12,20]. Endpoints
such as long-term morbidity, or a shift of focus to short-
and long-term respiratory changes in survivors of ARDS,
may be important when evaluating established and emer-
ging ARDS treatments. In a study evaluating 50 long-term
ARDS survivors, assessed a median of 5.5 years after ICU
discharge, 54% had impairment (defined as < 80% pre-
dicted value) in at least one pulmonary function measure,
including decreases in FEV1/FVC ratio consistent with air-
flow obstruction in 16 (32%), residual volume in 14 (28%),
TLC in 10 (20%), and diffusing capacity in 8 (16%) patients.
Seven patients (14%) had multiple pulmonary function
abnormalities. Overall, ARDS survivors described a 25%
reduction in physical and physical role function compared
with age- and sex-matched controls (P < 0.001). In addi-
tion, those with more than one pulmonary function
Table 2 Baseline oxygenation and respiratory parameters
Parameter Statistics Placebo Inhaled
NO
P Value
PaO2, mm Hg N 41 50
Mean ± SD 84.8 ± 21.4 90.6 ± 19.1
Median 81 86 0.068
PaCO2, mm Hg N 41 50
Mean ± SD 39.9 ± 7.7 40.8 ± 8.4
Median 41 39 0.728
SpO2,% N 41 50
Mean ± SD 95.1 ± 2.6 96.5 ± 2.6
Median 96 97 0.012
FiO2 N 41 50
Mean ± SD 0.65 ± 0.13 0.68 ± 0.16
Median 1 1 0.517
PEEP, cm H2O N 41 51
Mean ± SD 9.5 ± 1.7 9.8 ± 2.5
Median 10 10 0.748
PaO2/FiO2 ratio N 41 50




Median 132 130 0.774
Ventilator rate, breaths/min N 41 50
Mean ± SD 14.6 ± 4.4 13.1 ± 4.2 0.069
Tidal volume, mL/kg N 39 49
Mean ± SD 9.1 ± 1.7 10.3 ± 2.5 0.548
Mean airway pressure, cm H2O N 37 46
Mean ± SD 18.3 ± 7.1 16.9 ± 5.2 0.488
FiO2, fraction of inspired oxygen; N, number; NO, nitric oxide; PaCO2, arterial pressure of CO2; PaO2, partial pressure of arterial oxygen; PEEP, positive-end
expiratory pressure; SpO2, pulse oximetric oxygen saturation.
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Figure 2 Aggregate of individual subject data of daily change (mean ± SD) from baseline parameter for FiO2 through day 28; FiO2,
fraction of inspired oxygen; NO, nitric oxide.
Figure 3 Aggregate of individual subject data of daily change (mean ± SD) from baseline parameter for PEEP through day 28. NO,
nitric oxide; PEEP, positive-end expiratory pressure.
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abnormality had significantly decreased health-related QoL
parameters (that is, general/mental health, physical/social
function, and vitality) compared with those having one or
no abnormalities [21].
While part of a larger study examining the short-term
(28-day) effects of iNO on mortality and need for
assisted breathing, this six-month follow-up assessment
is the first prospective analysis evaluating iNO effects on
long-term pulmonary function in ARDS survivors. The
original clinical trial [19], as well as a meta-analysis of
12 randomized controlled trials in ALI or ARDS
patients [20], indicated no significant benefit of iNO in
decreasing mortality and only transient effects on phy-
siological endpoints, such as PaO2/FiO2 ratio. The
results of this six-month follow-up indicate an associa-
tion between iNO and better PFT results at six months
post-treatment. The patients receiving iNO had less
restrictive defect as reflected by higher FEV% predicted,
FVC % predicted and TLC. This association of iNO
treatment with reduced restrictive defect was not
accompanied by a significantly higher CO diffusion and
raises the question of potential systemic effect of iNO
on muscle function. The effects of iNO on systemic tis-
sue beds is a rapidly expanding, but only recently recog-
nized, area of research discovery.
The clinical significance of longer-term lung function
and QoL in ARDS survivors has been examined.
Although not linked in all studies, results from one
long-term follow-up of ARDS survivors indicated that
both FEV1 and FVC at 12 months post-episode were
correlated with the physical function domain of two
validated QoL questionnaires [14].
Additionally, the cumulated aggregate per-subject
values for FiO2, PEEP, and PaO2/FiO2 exposure days,
Figure 4 Aggregate of individual subject data of daily change (mean ± SD) from baseline parameter for P/F ratio through day 28. NO,
nitric oxide; PF, PaO2/FiO2 ratio.
Table 3 Duration of exposure parameters (AUC) during







Inhaled NO (ppm days)a 0 114 ± 102 NA
FiO2 (% days) 7.6 ± 4.7 6.3 ± 4.5 0.151
PEEP (mmHg days) 113.4 ± 81.1 96.3 ± 75.9 0.261
aValues are mean ± SD unless otherwise indicated. AUC, area under the curve;
FiO2, fraction of inspired oxygen; N, number; NO, nitric oxide; PaO2, partial
pressure of arterial oxygen; PEEP, positive-end expiratory pressure.
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while not reaching statistical significance, were less in
the iNO-treated patients compared with those in the
group treated with placebo. Taken together, the differ-
ences in six-month PFTs, as well as the aggregate oxyge-
nation exposure data, suggest a potential long-term
physiologic effect of iNO on lung function in ARDS
survivors.
There was an increased incidence of morbid obesity in
placebo patients in the study. As patients with morbid
obesity have an increased risk for pulmonary complica-
tions, this could be hypothesized to partially explain
some of the results. Regardless of the presence or
absence of morbid obesity, analyses showed that the
treatment effect remained the same (Additional files 1,
2, 3 and 4). Thus, the effects seen at six months are not
explained by the imbalance in number of patients with
morbid obesity between placebo and treatment groups.
iNO exerts its physiologic effects via cGMP-mediated
relaxation of the vascular smooth muscle and selective
dilation of the pulmonary vasculature. In addition, sev-
eral other potential mechanisms may underlie better
performance of iNO on pulmonary function. ARDS is
associated with pronounced elevations in multiple
inflammatory markers [22,23] and several studies have
suggested that these may be attenuated by iNO. Studies
with experimental animals [24] and ARDS patients [25]
have shown that iNO significantly decreases pulmonary
concentrations of IL-8 and neutrophils, as well as signif-
icantly inhibiting the formation of platelet-leukocyte
aggregates (an effect correlated with an NO-dependent
inhibition of platelet P-selectin expression). This may
potentially lead to improvement of microcirculation in
vascular beds, including muscle [26]. In another study
with ARDS patients, iNO was found to significantly
decrease H2O2 production and b2-integrin CD11b/CD18
expression by polymorphonuclear leukocytes. In addi-
tion, iNO decreased IL-6 and IL-8 concentrations in
bronchoalveolar lavage (BAL) fluid [27]. The well-
known mechanism of action for iNO (for example,
cGMP-mediated vasodilatation) likely explains the
decreased duration of FiO2 and PEEP exposure in the
original 28-day trial; the aforementioned insight into
other mechanisms of iNO in ARDS patients offers addi-
tional focus for research regarding long-term effects in
ARDS survivors.
In the original study, iNO did not improve short-term
mortality in patients with ARDS, despite transient phy-
siologic benefit [19]. With ARDS patients in general,
26% to 44% of deaths typically occur within 72 hours of
ARDS onset; these deaths are more often attributable to
events such as sepsis with multiple organ failure (30% to
50%) than to respiratory failure (13% to 19%) [28]. In
addition, changes in oxygenation sustained for only 24
hours with iNO have been shown to be insufficient to
alter mortality in patients with ARDS/ALI [20]. Given
these data, short-term outcomes with treatments such
as iNO may not prove clinically impactful; however, the
longer-term impact of iNO treatment in ARDS survi-
vors, based on the data herein and the potential
mechanisms of iNO in ARDS patients, warrant addi-
tional investigation.
Limitations
This analysis had limitations, primarily: 1) the large per-
centage of subjects lost to follow-up who did not have
Table 4 Pulmonary function test results at six months
Parameter Statistics Placebo Inhaled NO P
Value
FEV1, L N 41 51




Mean ± SD 69.51 ± 28.97 80.23 ± 21.21 0.042
FEV1/FVC, % N 40 51




Mean ± SD 87.92 ± 19.77 96.14 ± 13.79 0.033
FVC, L N 41 51




Mean ± SD 69.84 ± 27.40 83.78 ± 19.38 0.019
FEF25-75%, L/sec N 41 51




Mean ± SD 62.96 ± 36.26 72.50 ± 27.71 0.154
FRC, L N 33 44




Mean ± SD 78.19 ± 29.95 93.98 ± 25.55 0.109
TLC, L N 32 44














Mean ± SD 65.96 ± 23.23 71.02 ± 20.79 0.492
FEF, forced expiratory flow; FEV1, forced expiratory volume in 1 second; FRC,
functional residual capacity; FVC, forced vital capacity; N, number; NO, nitric
oxide; TLC, total lung capacity.
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Figure 5 Mean percent predicted pulmonary function comparisons between placebo and inhaled nitric oxide. NO, nitric oxide.
Table 5 Comparison of baseline demographic and clinical characteristics between survivors and patients without six
month follow-up
Parameter Survivors No 6-Month Follow-up P-Value
Age (years) N 92 293
Mean ± SD 46.4 ± 15.9 50.9 ± 17.4 0.044
Range 16.8 - 84.0 17.6 - 87.0
Sex, n (%) Male 44 (47.8%) 161 (54.9%) 0.281
Female 48 (52.2%) 132 (45.1%)
Race, n (%) Caucasian 77 (83.7%) 227 (77.5%) 0.423
Black 9 (9.8%) 44 (15.0%)
Other 6 (6.5%) 22 (7.5%)
Height (cm) N 90 277
Mean ± SD 169.1 ± 10.2 169.2 ± 11.6 0.856
Weight (kg) N 92 292
Mean ± SD 80.5 ± 21.9 79.4 ± 20.1 0.840
Causes of ARDS,a n (%)
Pneumonia 35 (38.0%) 142 (48.5%) 0.093
Toxic Gas Inhalation 0 (0%) 0 (0%) 1.000
Acute Pancreatitis 4 (4.3%) 12 (4.1%) 1.000
Masssive Blood Transfusion 15 (16.3%) 31 (10.6%) 0.144
Fat Emboli 3 (3.3%) 7 (2.4%) 0.708
Aspiration Pneumonitis 18 (19.6%) 72 (24.6%) 0.397
Pulmonary Contusion 18 (19.6%) 51 (17.4%) 0.642
Post-Partum ARDS 2 (2.2%) 1 (0.3%) 0.143
Multiple Trauma 29 (31.5%) 74 (25.3%) 0.280
Elective or Emergency Surgical Procedures 29 (31.5%) 100 (34.1%) 0.705
Patient History, n (%)
Preexisting steroid use 11 (12.0%) 34 (11.6%) 1.000
Asthma 9 (9.8%) 30 (10.2%) 1.000
COPD 12 (13.0%) 36 (12.3%) 0.857
Tobacco use 47 (51.1%) 121 (41.3%) 0.117
Other lung diseaseb 0 (0%) 18 (6.1%) 0.009
aPatients may have more than one cause of ARDS. bPatients may have more than one preexisting disease including: cancer, bronchitis, amiodarone toxicity, and
status/post lung resection. ARDS, acute respiratory distress; COPD, chronic obstructive pulmonary disorder; N, number; NO, nitric oxide.
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PFTs performed at six months; and 2) the inability to
obtain premorbid PFTs. Even though the former consti-
tuted a protocol violation, the reasons for this occurring
are not available, potentially influencing the results via
significant bias or confounding. Additionally, while the
lack of premorbid PFTs would have provided valuable
insight, from a practical study standpoint, obtaining
these values was not possible. The fact that the baseline
characteristics between groups were very similar, espe-
cially with respect to severity of illness, co-morbid
chronic respiratory conditions and use of inhaled corti-
costeroids, suggests that these potential influences may
have been minimized.
There was a small but statistically significant differ-
ence in baseline SpO2 that favored the iNO group. Tidal
volume was higher, and ventilator rate and mean airway
pressure were lower in patients receiving iNO; however,
there was no consistent pattern of these small, non-sig-
nificant differences that would support an influence on
pulmonary function at the six-month follow-up. Finally,
the inclusion criteria of the original study did not
exclude preexisting lung disease and treatment assign-
ment was not stratified on that basis [19].
Conclusions
While current clinical research regarding ARDS treat-
ment has focused on mortality and short-term effects of
treatment, it is important to consider chronic lung
effects in ARDS survivors, which could be a cause of
long-term morbidity and reduction of QoL in this popu-
lation. Results from this six-month analysis show that
ARDS survivors who received iNO had significantly bet-
ter PFT parameters versus those who received placebo,
as indicated by decreased restrictive defect.
These results support consideration of further clinical
trials to determine the longer-term effects of iNO on
the incidence and severity of chronic lung disease in
ARDS patients. Additional outcomes that should be
explored include measures of health-related QoL,
healthcare utilization, and overall patient management
cost.
Key messages
1. Multiple clinical trials have failed to show a survi-
val benefit of inhaled nitric oxide (INO) in ARDS.
2. Inhaled nitric oxide has known actions that might
be associated with long term improvement in pul-
monary function
3. Long term functional outcome differences might
be present for acute interventions in ARDS that tar-
get 28 day mortality even if primary outcome end-
point is not met.
4. In a large randomized clinical trial that failed to
demonstrate survival benefits when ARDS was
treated with INO, PFTs performed at 180 days in a
survivor sample demonstrated less restrictive defect
in survivors given INO.
5. Additional studies are needed to prove or disprove
this secondary endpoint analysis.
Additional material
Additional file 1: Pulmonary function test results at six months in
subjects with morbid obesity. Demonstrates full pulmonary function
studies in enrolled patients who were morbidly obese at time of
enrollment.
Additional file 2: Pulmonary function test results at six months in
subjects without morbid obesity. Demonstrates full pulmonary
function studies in enrolled patients who were not morbidly obese at
time of enrollment.
Additional file 3: Obesity effect on pulmonary function test results
at six months in subjects treated with placebo. This data
demonstrate the effect of obesity on pulmonary function tests
performed six months from the enrollment in the study who were
treated with placebo.
Additional file 4: Obesity effect on pulmonary function test results
at six months in subjects treated with INO. This data demonstrate the
effect of obesity on pulmonary function tests performed 6 months from
the enrollment in the study who were treated with inhaled nitric oxide.
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